Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iniparib - TriAct Therapeutics

Next Previous
Drug Profile

Iniparib - TriAct Therapeutics

Alternative Names: BSI-201; SAR-240550

Latest Information Update: 22 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BiPar Sciences
  • Developer BiPar Sciences; National Cancer Institute (USA); Sanofi; TriAct Therapeutics
  • Class Antineoplastics; Benzamides; Iodobenzenes; Nitro compounds; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Discontinued Brain metastases; Breast cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Uterine cancer

Most Recent Events

  • 22 Apr 2025 TriAct Therapeutics plans a regulatory filing for EMA orphan status in second quarter of 2025 (TriAct Therapeutics Communication, April 2025)
  • 21 Apr 2025 Phase-III clinical trials in Glioma (First-line therapy) (unspecified route), before April 2025 (TriAct Therapeutics Communication, April 2025)
  • 21 Apr 2025 Iniparib receives Rare Pediatric Disease Designation (RPDD) from the US FDA for glioma, before April 2025 (TriAct Therapeutics Communication, April 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top